A new study has shown that the preventive drugs of HIV are available within the United States and portrayed as equally safe with effective measures; whereas, the only price is the vast difference between them.
Researchers say that PrEP (pre-exposure prophylaxis) is known as a sizable minority for the patients who are switched to cheaper from older formulations to the much pricier medications and newer ones. Among the many cases are not warranted.
Among Two PrEP Medications, One Is Cheaper Which Presents Equal Work
It must be noted here that there is no drug effects on this disease yet and experts are still researching the issues and symptoms as well as results offered by various medicines. While offering two options the cost and effect of both must be evaluated at an equal level and accordingly, the price must be set said an expert.
According to this study, the two PrEP medications are made with antiretroviral pills which are tended to be effective with 99 percent which prevents HIV infection in the people who are facing higher risks for the catch of the virus.
The U.S. Food and Drug has received approvals which include new generic combos known as TDF or FTC and emtricitabine of tenofoviralafenamide with TAF or FTC of emtricitabine. These mentioned combos are represented by the brand names called Truvada, and Descovy.
Researchers stated that “every formulation is having its own set with the side effects called TDF or FTC or Truvada” which are associated with small reductions for kidney functions and other bone mineral densities.
The term Descovy is associated with higher cholesterol rates and minor weight gains. The research team stated that there is a huge difference between the two prices of medications.
In the United States, TDF or FTC of generic medications are available with new costs and little amounts like $30 every month comparatively $1,800 for every month with the brand name called Descovy.
Researchers say that this theory has shown a significant difference in price where some of the patients are switched for expensive drugs. On this point, researchers wanted to find the clinical reasons for the switch which had taken place.
Julia Marcus is the lead researcher and author of this study states that “there are many critical barriers which are held with an equitable and broad usage of PrEP in the United States which are costed in both inclusive for actual and perceived costs”.
In a recent university news release, “the access of generic TDF/FTC is revolutionized by the access if PrEP which had an opportunity for the missed resources with an investment on expensive medications without justifications for clinical outcomes”.
The FDA team had approved the Descovy brand for digging the issue and tracking the data with TDF/FTC prescriptions for the PrEP medication.
Investigators had found that over 343 i.e., 12 percent of the patients were switched to Descovy within the first available year. On this point, the kidney dysfunctions are associated with the switch for ewer drugs and having less likely for patients with the highest cholesterol.
The theory of this study is based on the heart, bone, and kidney risks which are switched to 7 percent of Descovy with a good clinical reason and outcomes.
HIV experts state that many of the patients who are switched to PrEP medications are not required for having risk factors and developments of kidney dysfunctions, diabetes, and high blood pressures with 27 percent. This theory is indicated clinically.
This new study reminds about the selection of medications for patients to see the better outcomes which are accounted with medical conditions with pharmaceutical options like cost-effective, etc.
